
CARB-X announced today that it has awarded biotechnology company ArrePath, of Princeton, New Jersey, $3.7 million to execute a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel portion of pathogenic bacteria for treating complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales bacteria.
Using an artificial intelligence and machine-learning–enabled (AI/ML) approach, ArrePath has identified a series of inhibitors with a novel mechanism of action against a highly conserved but previously unexploited target in gram-negative bacteria.
Could act against vast majority of MDR Enterobacterales
If developed as hoped, ArrePath's novel antibiotic class will be active against the vast majority of MDR Enterobacterales infections, representing an important new tool in the fight against antimicrobial resistance. ArrePath's inhibitors have attributes that suggest they can be administered orally as well as by the intravenous (IV) route. This would allow hospitalized patients being treated via IV to switch to oral medicine when appropriate.
"CARB-X is excited to support ArrePath in advancing its new antibiotic targeting multidrug-resistant Enterobacterales," said Erin Duffy, PhD, chief of research and development with CARB-X. "This could significantly improve treatment options for complicated urinary tract infections, especially in outpatient and community settings."
This could significantly improve treatment options for complicated urinary tract infections.
"We are thrilled to have received this prestigious award from CARB-X, which not only provides external validation of our proprietary AI/ML platform but also allows us to rapidly advance a novel class of antibiotics that is so desperately needed for the treatment of multidrug-resistant gram-negative infections," said Kevin Krause, MBA, ArrePath president and CEO.